Literature DB >> 31932041

The use of mice lacking type I or both type I and type II interferon responses in research on hemorrhagic fever viruses. Part 1: Potential effects on adaptive immunity and response to vaccination.

Elizabeth C Clarke1, Steven B Bradfute2.   

Abstract

For more than 20 years, researchers have used laboratory mice lacking type I or both type I and type II interferon (IFN) responses to study viruses that cause hemorrhagic fever (HF) in humans. Whereas immunocompetent mice do not become ill when infected with Ebola, Lassa, dengue and other HF viruses, IFN-deficient mice typically develop severe or fatal disease when inoculated with these pathogens. The ease of employment of these "mouse models" has led to their extensive use in biocontainment laboratories to assess the efficacy of novel vaccines, often without consideration of whether adaptive immune responses in IFN-deficient mice accurately mirror those in humans. Failure to consider these questions may lead to inappropriate expectations of the predictive value of mouse experiments. In two invited articles, we investigate this question. This paper examines how the lack of type I or both type I and type II IFN signaling may affect the development of adaptive immune responses in mice and the outcome of vaccine studies. A second article reviews the published literature on the use of IFN-deficient mice for the assessment of novel vaccines against HF viruses.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Hemorrhagic fever viruses; Immune responses; Interferon-deficient mice; Type I IFNs; Type II IFNs; Vaccines

Year:  2020        PMID: 31932041     DOI: 10.1016/j.antiviral.2019.104703

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  10 in total

Review 1.  The use of mice lacking type I or both type I and type II interferon responses in research on hemorrhagic fever viruses. Part 2: Vaccine efficacy studies.

Authors:  Marko Zivcec; Christina F Spiropoulou; Jessica R Spengler
Journal:  Antiviral Res       Date:  2020-01-22       Impact factor: 5.970

2.  Identification of Single Amino Acid Changes in the Rift Valley Fever Virus Polymerase Core Domain Contributing to Virus Attenuation In Vivo.

Authors:  Belén Borrego; Sandra Moreno; Álvaro López-Valiñas; Nuria de la Losa; Friedemann Weber; José Ignacio Núñez; Alejandro Brun
Journal:  Front Cell Infect Microbiol       Date:  2022-04-28       Impact factor: 6.073

3.  The host inflammatory response contributes to disease severity in Crimean-Congo hemorrhagic fever virus infected mice.

Authors:  Joseph W Golden; Xiankun Zeng; Curtis R Cline; Jeffrey M Smith; Sharon P Daye; Brian D Carey; Candace D Blancett; Charles J Shoemaker; Jun Liu; Collin J Fitzpatrick; Christopher P Stefan; Aura R Garrison
Journal:  PLoS Pathog       Date:  2022-05-19       Impact factor: 7.464

Review 4.  Severe fever with thrombocytopenia syndrome virus: emerging novel phlebovirus and their control strategy.

Authors:  Mark Anthony Casel; Su Jin Park; Young Ki Choi
Journal:  Exp Mol Med       Date:  2021-05-06       Impact factor: 8.718

5.  T-Cells and Interferon Gamma Are Necessary for Survival Following Crimean-Congo Hemorrhagic Fever Virus Infection in Mice.

Authors:  David W Hawman; Kimberly Meade-White; Shanna Leventhal; Aaron Carmody; Elaine Haddock; Kim Hasenkrug; Heinz Feldmann
Journal:  Microorganisms       Date:  2021-01-29

6.  Immunocompetent mouse model for Crimean-Congo hemorrhagic fever virus.

Authors:  David W Hawman; Kimberly Meade-White; Shanna Leventhal; Friederike Feldmann; Atsushi Okumura; Brian Smith; Dana Scott; Heinz Feldmann
Journal:  Elife       Date:  2021-01-08       Impact factor: 8.140

7.  Comparing immunogenicity and protective efficacy of the yellow fever 17D vaccine in mice.

Authors:  Ji Ma; Robbert Boudewijns; Lorena Sanchez-Felipe; Niraj Mishra; Thomas Vercruysse; Dieudonné Buh Kum; Hendrik Jan Thibaut; Johan Neyts; Kai Dallmeier
Journal:  Emerg Microbes Infect       Date:  2021-12       Impact factor: 7.163

8.  Liver transcriptomics reveals features of the host response in a mouse model of dengue virus infection.

Authors:  Wenjiang Zheng; Qian Yan; Zonghui Li; Xianyang Wang; Peng Wu; Feng Liao; Zizhao Lao; Yong Jiang; Xiaohong Liu; Shaofeng Zhan; Geng Li
Journal:  Front Immunol       Date:  2022-08-26       Impact factor: 8.786

Review 9.  Animal Models of Lassa Fever.

Authors:  Rachel A Sattler; Slobodan Paessler; Hinh Ly; Cheng Huang
Journal:  Pathogens       Date:  2020-03-06

10.  The Chimeric Binjari-Zika Vaccine Provides Long-Term Protection against ZIKA Virus Challenge.

Authors:  Jessamine E Hazlewood; Bing Tang; Kexin Yan; Daniel J Rawle; Jessica J Harrison; Roy A Hall; Jody Hobson-Peters; Andreas Suhrbier
Journal:  Vaccines (Basel)       Date:  2022-01-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.